19-Year-Old Woman Presents With Anterior Cervical Area Lymphadenopathy

Poll

A 19-year-old woman presents with anterior cervical area lymphadenopathy. After further evaluation, a lymph node biopsy is performed. What is your diagnosis?

A 19-year-old woman presents with anterior cervical area lymphadenopathy. According to the histopathology image below, what is your diagnosis?

What is your diagnosis?

A. Lymphadenitis
B. Hodgkin lymphoma
C. Large cell lymphoma
D. Castleman disease

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
2 experts in this video
Related Content
Developers have initiated a phase 1 clinical trial evaluating the safety, tolerability, and early anti-tumor activity of CID-078 in advanced solid tumors.

CID-078 Earns FDA Orphan Drug Designation in Small Cell Lung Cancer

Roman Fabbricatore
June 17th 2025
Article

Developers have initiated a phase 1 clinical trial evaluating the safety, tolerability, and early anti-tumor activity of CID-078 in advanced solid tumors.

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
June 16th 2025
Podcast

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

Ponatinib Shows Clinical Benefit Over Imatinib in MRD-Positive Ph+ ALL Post Induction

Ponatinib Shows Clinical Benefit Over Imatinib in MRD-Positive Ph+ ALL Post Induction

Chris Ryan
June 17th 2025
Article

Ponatinib extended EFS and PFS in patients with newly diagnosed, Ph-positive acute lymphoblastic leukemia who did not achieve MRD negativity after induction.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

30 Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2– Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial

30 Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2– Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial

Aarti Chawla;Komal Jhaveri;Patrick Neven, MD, PhD;Monica Lis Casalnuovo;Sung-Bae Kim;Eriko Tokunaga;Philippe Aftimos;Cristina Saura;Joyce A. O’Shaughnessy;Nadia Harbeck, MD, PhD;Lisa A. Carey, MD;Guiseppe Curigliano;Antonio Llombart-Cussac;Elgene Lim, MBBS, FRACP, PhD;María de la Luz García Tinoco;Joohyuk Sohn;Andre Mattar;Qingyuan Zhang;Chiun-Sheng Huang;Chih-Chiang Hung;Jorge Luis Martinez Rodriguez;Manuel Ruiz Borrego
June 16th 2025
Article
Similar response rates and safety profiles were observed with subcutaenous and intravenous isatuximab in the phase 3 IRAKLIA study.

Subcutaneous Isatuximab Shows Noninferior Efficacy in Multiple Myeloma

Kristi Rosa
June 16th 2025
Article

Similar response rates and safety profiles were observed with subcutaenous and intravenous isatuximab in the phase 3 IRAKLIA study.